Abstract
Introduction
This analysis examines the historical and forecast performance for Chugai in
the prescription pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Key reasons to purchase this research
- Benchmark Chugai' s performance against key rivals in the prescription
pharmaceutical sector
- Evaluate the impact of Chugai' s alliance with Roche, including forecast
strong growth for the Genentech-derived mAb portfolio in Japan
- Assess the forecast performance of Actemra, the first monoclonal antibody
product to be developed and successfully launched by a Japanese company
| 
View Cart
